Cipla has entered into a significant agreement with Eli Lilly and Company (India) to sell Tirzepatide (brand Yurpic), a drug for Type 2 Diabetes and weight loss, in India. Lilly will manufacture and supply the drug, while Cipla will handle its distribution and promotion. Following this news, Cipla's shares saw a decline.
Cipla’s shares: Cipla, a major pharmaceutical company in India, is set to sell Tirzepatide (brand name Yurpic), a drug for Type 2 Diabetes and weight loss, in India. For this purpose, the company has collaborated with Eli Lilly and Company (India). Under the agreement, Lilly will manufacture and supply the drug, while Cipla will be responsible for its distribution and promotion. This strategic move aims to increase the drug's accessibility nationwide. Following the announcement of the agreement, Cipla's shares dropped by 3.35%.
Details of the Major Deal
Domestic pharmaceutical company Cipla and Eli Lilly and Company (India) have agreed to sell Tirzepatide, a drug for Type 2 Diabetes and chronic weight management, under the new brand name Yurpic in India. Lilly had previously introduced Tirzepatide in India under the brand name Mounjaro in March 2025.
Under this agreement, Cipla will gain the rights to distribute and promote the Yurpic brand of Tirzepatide in India. The objective is to enhance the drug's availability, including in cities where Lilly does not yet have a b presence. This move by Cipla will further broaden the drug's reach across the country.
Drug Price
The price of this drug will be kept similar to Mounjaro. Winslow Tucker, President and General Manager of Eli Lilly India, stated that the commercial agreement with Cipla provides an opportunity to launch a second brand of Tirzepatide in India. This will improve patient access to new treatments for chronic diseases in the country.
Tucker explained that the problems of Type 2 Diabetes and obesity are rapidly increasing in India. The widespread availability of Yurpic will ensure that more patients can benefit from this innovative therapy.
Decline in Cipla's Shares
Following this news, Cipla's shares experienced a decline. According to BSE data, Cipla's share price fell by 3.35% to ₹1,590 on Friday. The company's share opened at ₹1,639.95 in the morning. At 10:15 AM, the share was trading at ₹1,598, down by 2.87%. The day before, the company's share had closed at ₹1,645.25.
Experts suggest that this current decline in shares could be a typical market reaction. Investors are anticipating fluctuations in share value, considering the agreement and the drug's future prospects.
Benefits of Tirzepatide and Yurpic
Tirzepatide is considered beneficial for patients with Type 2 Diabetes. This medication helps control blood sugar and is also effective in reducing obesity. Its distribution and promotion under the Yurpic brand, through Cipla, will reach more cities and rural areas.
According to doctors and pharmaceutical experts, the introduction of drugs like Tirzepatide to the market is a significant step for patients struggling with diseases like diabetes and obesity. It will provide patients with easier access to the latest and most effective medications.
